A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer or Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Taselisib (Primary) ; Docetaxel; Paclitaxel
- Indications Breast cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Genentech
- 31 Aug 2018 Biomarkers information updated
- 24 Aug 2017 Status changed from active, no longer recruiting to completed.
- 09 May 2017 Planned End Date changed from 1 Dec 2017 to 4 Oct 2017.